Both methods have shown prominent weight loss results, documented in clinical studies
Since its discovery in 1984 by Svetlana Mosjov, GLP-1 and its analogs (such as semaglutide, liraglutide, and dulaglutide) have rapidly become cornerstone treatments for type 2 diabetes mellitus (T2DM) and obesity
The appetite-suppressing effects of tirzepatide are not limited to the peak window
So, in March 2023, Madison started GLP-1 medication through Claya, a weight loss and wellness company
The best candidates for injectable weight loss are overweight or obese individuals who want to lose a significant amount of weight
Calibrate uses this data-driven approach to intervene with a course correction if the patient biological response does not match the expected curve